Search Results for: drug patents

9 November 2016 – WTO TRIPS Council – WHO’s intervention on the Report of the UN High-Level Panel on Access to Medicines

Posted on by Thiru

On Wednesday, 9 November 2016, the World Health Organization (WHO) delivered the following statement at the World Trade Organization’s (WTO) TRIPS Council’s discussions of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines.

COUNCIL FOR TRIPS

8-9 NOVEMBER 2016

WHO STATEMENT

13. THE UNITED NATIONS SECRETARY-GENERAL’S HIGH LEVEL PANEL REPORT ON ACCESS TO MEDICINES

Thank you very much for giving WHO the opportunity to share our feedback on the Report of the High-Level Panel on Access to Medicines.

Continue Reading →

2016: Kite Pharma, KEI Comments on NIH Proposed Exclusive License for Cancer Treatment

Posted on by Claire Cassedy

Today, KEI submitted comments to the Notice published in the Federal Register on October 5, 2016, entitled “Prospective Grant of Exclusive Patent License: Development of Anti-CD70 Chimeric Antigen Receptors for the Treatment of CD70 Expressing Cancers.” KEI’s comments addressed issues with the NIH’s processes for granting exclusive licenses, and transparency in those licenses, resulting data, trials, pricing, and revenue.
Continue Reading →

56 NGOs ask US Government enable export of low cost generic versions Xtandi to developing countries

Posted on by Zack Struver

17 OCTOBER 2016

CONTACT: Zack Struver, zack.struver@keionline.org, +1-202-332-2670, or Paul Davis, pdavis@keionline.org, +1-202-332-2670

Note: Letter from Biolyse to HHS here: /wp-content/uploads/28-sept-2016-biolyse-to-hhs-letter.pdf
Letter from NGOs to HHS here: /wp-content/uploads/17-oct-2016-civil-society-letter-xtandi.pdf

Washington, DC — Today, over 50 patient, senior citizen, global health, development, social justice, and faith groups urged the United States Government to use its rights in a federally funded patented invention, and accept the request by a Canadian generic drug manufacturer (Biolyse Pharma) to enter into an agreement to manufacture and export an affordable version of the taxpayer-funded prostate cancer drug enzalutamide to South Africa and other countries with low per-capita incomes relative to the United States.
Continue Reading →

Uncategorized

Summary of Report of United Nations Secretary-General’s High-Level Panel on Access to Medicines

Posted on by Zack Struver

On September 14, 2016, the United Nations Secretary-General’s High-Level Panel on Access to Medicines released its report, in which they had a mandate to “review and assess proposals and recommend solutions for remedying the policy incoherence between the justifiable rights of inventors, international human rights law, trade rules and public health in the context of health technologies.”[1]

Continue Reading →

KEI Statement on United Nations Secretary-General’s High-Level Panel on Access to Medicines Report

Posted on by KEI Staff

On September 14, 2016, the United Nations Secretary-General’s High-Level Panel on Access to Medicines issued its long-awaited report, which addressed the policy incoherencies between intellectual property, trade, human rights, innovation, and public health.

The report is available here: http://www.unsgaccessmeds.org/final-report/
Continue Reading →

SCP 24 – A fruitful discussion?

Posted on by Staff

30 June 2016

By Sophia Simon

The World Intellectual Property Organization’s (WIPO) Standing Committee on the Law of Patents (SCP) plays a significant role as the United Nation’s only dedicated, multilateral forum for the discussion on patents. The WIPO SCP convened for its 24th session in Geneva from 27 June 2016 to 30 June 2016.

Continue Reading →

SCP24: KEI statement on exceptions and limitations to patent rights

Posted on by Thiru

SCP24

27 June 2016

KEI statement on exceptions and limitations to patent rights

In relation to limitations and exceptions, we recall Brazil’s prescient submission, document SCP/14/7 (tabled in January 2010) which called attention to the lack of policy coherence in a world where in certain international fora, countries endorse the use of compulsory licensing to promote access to medicines for all, and in separate fora, criticize developing countries for actually considering or issuing such compulsory licenses.

Continue Reading →

Uncategorized

Novartis complaints over public interest declaration debunked

Posted on by Andrew Goldman

More on this dispute at /colombia

In response to the recent announcement from Colombia’s Ministry of Health that a public interest declaration regarding imatinib will be issued in a matter of days, Novartis issued a statement that criticized the forthcoming action, saying, “We have consistently said that Declarations of Public Interest can be important and legitimate tools to be used only in exceptional circumstances,” and saying “this is simply not the case in Colombia.” Continue Reading →

Uncategorized